Heart Microcurrent Implants Show Early Promise but Need Stronger Evidence

Cardiac microcurrent therapy is an experimental implant approach intended to improve heart function in patients whose hearts pump poorly despite treatment. Heart failure can limit exercise tolerance and daily independence, making improvements in physical capacity especially meaningful. New conference findings suggest potential benefits, but the evidence remains preliminary and does not establish the therapy as routine care.

The original randomized trial included 65 patients with heart failure not caused by reduced blood supply. At six months, surgical implantation was associated with improvements in pumping function, symptoms, exercise capacity, and quality of life. A later analysis reassessed exercise tests through an independent laboratory blinded to treatment assignment, addressing concerns about inconsistent testing and measurement bias.

That reassessment included 42 patients, averaging about 62 years old; more than 70% were men. Weight adjusted peak oxygen uptake improved by 2.70 milliliters per kilogram per minute with treatment. Improvements in exercise intensity and predicted oxygen uptake favored the implant and reached statistical significance. However, the difference in absolute peak oxygen uptake did not reach that threshold.

Researchers propose that tiny electrical currents could reduce activity in scar forming cells, helping make heart muscle less stiff. This remains a proposed mechanism, not a proven explanation for the clinical findings. Investigators also presented early work on placing the device under the skin rather than surgically on the heart, but the supplied article ends before reporting those results.

For patients, these findings support further research rather than seeking the implant outside appropriate clinical studies. Established heart failure treatment remains the priority. Important uncertainties include the small reassessment sample, the analysis being conducted after the original trial, and limited information about safety and durability. Even specialists questioned the unusually large reported benefit. Larger randomized trials with rigorous controls must confirm whether improvements are consistently reproducible and clinically meaningful.